The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program...
FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma
FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma
No comments:
Post a Comment